Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Reuters Investment Profile
$20.00
Provider: Wright Reports
$75.00
Provider: Sadif Analytics Prime
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Medigen Biotechnology Corp announces phase III PI-88 clinical trial result


Sunday, 29 Dec 2013 06:42pm EST 

Medigen Biotechnology Corp:Says obtained positive result for the phase III clinical trial of PI-88, a early treatment drug of liver cancer. 

Company Quote

165.0
 --
26 Dec 2014